Systematic review of efficacy and safety of Xinmailong Injection in treatment of coronary heart disease complicated with heart failure

WEI Jing-jing1 ZHU Ming-jun2 WANG Yong-xia2 LI Bin2 PENG Guang-cao2 WANG Xin-lu2 YU Rui2

(1.Henan University of Chinese Medicine, Zhengzhou, Henan, China 450000)
(2.The First Affiliated Hospital of Henan University of CM, Zhengzhou, Henan, China 450000)

【Abstract】To systematically evaluate the efficacy and safety of Xinmailong Injection in the treatment of coronary heart failure. The Chinese databases including China National Knowledge Infrastructure (CNKI), Wanfang Data Knowledge Service Platform (WanFang), Chinese Biomedical Literature Service System (SinoMed), and Chongqing Weipu Database for Chinese Technical Periodicals (VIP) as well as foreign databases including PubMed, EMBase and Cochrane Library were searched to collect the randomized controlled trials (RCTs) about Xinmailong Injection in the treatment of coronary heart failure, with the retrieval time set from the inception of each database to February 2020. The literature screening, data extraction, and quality evaluation were conducted by two researchers independently according to the inclusion and exclusion criteria. RevMan 5.3 software was used for Meta-analysis. A total of 19 studies involving 1 922 patients were included, including 967 cases in the treatment group and 955 cases in the control group. All the clinical studies were low in quality. Meta-analysis results showed that Xinmailong Injection combined with routine basic treatment (RBT) could better reduce the BNP level (SMD = −3.34, 95% CI [−4.06, −2.63]) or NT-proBNP level, improve the heart function (RR = 1. 23, 95% CI [1.18, 1.29]) and LVEF (MD = 6.85, 95% CI [4.93, 8.76]), increase 6MWT (MD = 24.34, 95% CI [16.05, 32.64]) and VEGF (MD = 26.39, 95% CI [24.30, 28.49]), and decrease LVEDD (MD = −4.06, 95% CI [−6.33, −1.80]) in patients with coronary heart failure. Subgroup analysis suggested that the course of treatment may be related to the increase in LVEF. This study found that Xinmailong Injection can further alleviate clinical symptoms and relevant indicators of patients with coronary heart failure, without inducing serious adverse reactions. However, the evidence level concerning the effectiveness and safety of Xinmailong Injection in treating coronary heart failure needs to be further supported by more well-designed and standardized multi-center studies with a large sample size.

【Keywords】 Xinmailong Injection; coronary heart disease; heart failure; systematic review; randomized controlled trial; Meta-analysis;

【DOI】

【Funds】 National Key R&D Program of China (2019YFC1710000, 2019YFC1710003) Project for Building Evidence-Based Capacity of TCM by National Administration of Traditional Chinese Medicine (2019XZZX-XXG003) Innovative Technology Team in Henan Province (C20130050)

Download this article

    References

    [1] ZHANG M X, CAO H X. 冠心病中医研究 [M]. Beijing: China Press of Traditional Chinese Medicine Co., Ltd., 2010 (in Chinese).

    [2] MEMBERS W G, MOZAFFARIAN D, BENJAMIN E J, et al. Executive summary: heart disease and stroke statistics—2016 update: a report from the American Heart Association [J]. Circulation, 2016, 127 (1): 143.

    [3] Expert Committee on the Rational Use of Drugs, National Health Commission of the People’s Republic of China and Chinese Pharmacists Association. 心力衰竭合理用药指南 (第2版) [J]. Chinese Journal of the Frontiers of Medical Science (Electronic Version), 2019, 11 (7): 1 (in Chinese).

    [4] PANG W T, ZHANG J H, ZHAI J B, et al. Tongmai Yangxin Pills in treatment for angina pectoris of coronary heart disease: a systematic review of randomized clinical trails [J]. China Journal of Chinese Materia Medica, 2019, 44 (11): 2390 (in Chinese).

    [5] LI Q J, WANG Z G LIU Q, et al. 美洲大蠊研究现状及其研究中关键问题分析与展望 [J]. China Journal of Chinese Materia Medica, 2018, 43 (7): 1507 (in Chinese).

    [6] SUN W Q. Value of Xinmailong injection in the treatment of chronic heart failure [J]. Chinese Journal of Clinical Rational Drug Use, 2019, 12 (20): 3 (in Chinese).

    [7] International Society and Federation of Cardiology and World Health Organization Task Force on Standardization of Clinical Nomenclature. Nomenclature and Criteria for Diagnosis of Ischemic Heart Disease [J]. Chinese Journal of Cardiology, 1981, 9 (1): 75 (in Chinese).

    [8] BRAUNWALD E. Cardiology [M]. 5th Edition. Translated by Chen H Z. Beijing: People’s Medical Publishing House, 2000 (in Chinese).

    [9] China Society of Cardiology, Chinese Medical Association and Editorial Board of Chinese Journal of Cardiology. Guidelines for Diagnosis and Management of Chronic Stable Angina [J]. Chinese Journal of Cardiology, 2007, 35 (3): 195 (in Chinese).

    [10] China Society of Cardiology, Chinese Medical Association and Editorial Board of Chinese Journal of Cardiology. Chinese Guidelines for Diagnosis and Treatment of Heart Failure [J]. Chinese Journal of Cardiology, 2014, 42 (2): 98 (in Chinese).

    [11] China Society of Cardiology, Chinese Medical Association and Editorial Board of Chinese Journal of Cardiology. 中国心力衰竭诊断和治疗指南2018 [J]. Chinese Journal of Cardiology, 2018, 46 (10): 76 (in Chinese).

    [12] ZHENG Y Y 郑莜庾. 中药新药临床研究指导原则 (试行) [M]. Beijing: China Medical Science and Technology Press, 2002 (in Chinese).

    [13] ZHONG L H. 心脉隆注射液治疗老年性冠心病心力衰竭临床观察 [J]. Diet and Health, 2016, 3 (11): 94 (in Chinese).

    [14] ZHAO G Y, GUO K, YUAN Q W, et al. Therapeutic effect of Xinmailong injection on coronary heart disease with heart failure [J]. China Modern Doctor, 2019, 57 (19): 58 (in Chinese).

    [15] XU F, CAO J. 心脉隆注射液联合西药对冠心病心力衰竭患者的临床疗效 [J]. Chinese Traditional Patent Medicine, 2019, 41 (8): 2012 (in Chinese).

    [16] XIONG C F. 心脉隆治疗冠心病心衰疗效及对血浆NT-proBNP的影响 [D]. Chengdu: Chengdu University of TCM, 2014 (in Chinese).

    [17] WU Z F, CHEN W W, LIU X X. 心脉隆注射液对冠心病心力衰竭病人血清BNP、hsCRP、VEGF的影响 [J]. Chinese Archives of Traditional Chinese Medicine, 2017, 35 (9): 2433 (in Chinese).

    [18] WANG C F. 心脉隆注射液联合曲美他嗪治疗冠心病心力衰竭的疗效分析 [J]. Cardiovascular Disease Electronic Journal of Integrated Traditional Chinese and Western Medicine, 2015, 3 (20): 88 (in Chinese).

    [19] TENG M Z, WANG X Y. 心脉隆注射液联合曲美他嗪治疗冠心病慢性心力衰竭 (气阳两虚证)的临床观察 [J]. China Pharmacy, 2017, 28 (26): 3705 (in Chinese).

    [20] TANG H, LI J, HUANG Z H, et al Effect of Xinmailong on QT dispersion and clinical efficacy in patients with ischemic heart failure [J]. China Medicine, 2013, 8 (9): 1211 (in Chinese).

    [21] SONG Z J. 心脉隆治疗冠心病心力衰竭对血浆高敏C反应蛋白 (hs-CRP)和N末端B型钠肽前体 (NT-proBNP)的影响 [J]. Health Guide, 2018 (6): 237 (in Chinese).

    [22] SONG X X, YAN C H, ZHANG X T, et al. Clinical study on Xinmailong Injection combined with bisoprolol in treatment of coronary heart disease patients with heart failure [J]. Drugs & Clinic, 2016, 31 (5): 623 (in Chinese).

    [23] SHI H R, FENG Y P, YANG X Q, et al. 心脉隆注射液对冠心病心力衰竭病人血清BNP、hsCRP、VEGF的影响 [J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2016, 14 (2): 168 (in Chinese).

    [24] SHEN W Y, LI Y D, YANG S Z. The influence of Xinmailong Injection on cardiac function and plasma NT-proBNP level in patients with coronary heart disease with chronic heart failure [J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2017, 15 (7): 833 (in Chinese).

    [25] LIU P, GAO X L, YUAN J H, et al. The clinical efficacy of Xinmailong on heart failure in coronary heart disease and on the levels of hs-C-reactive protein and N-terminal B-type natriuretic peptide [J]. Chinese Journal of Geriatrics, 2017, 36 (5): 502 (in Chinese).

    [26] LI Z G, MA G F, YANG J, et al. Effects of Xinmailong Injection and bisoprolol on the hemodynamics and serum hs-CRP, BNP, VEGF levels in patients with heart failure caused by coronary heart disease [J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2018, 16 (4): 393 (in Chinese).

    [27] LI Z H, LI Y, LI Y. 心脉隆注射液结合硝普钠对冠心病慢性心力衰竭患者hs-CRP、CysC以及NT-proBNP水平的影响 [J]. Chinese Archives of Traditional Chinese Medicine, 2020, 38 (5): 182 (in Chinese).

    [28] LI D Q, ZHENG P, LIN S. 心脉隆注射液对冠心病心衰患者血清hsCRP和NT-proBNP及高敏 CTn-I的影响观察 [J]. Journal of Huaihai Medicine, 2016, 34 (6): 724 (in Chinese).

    [29] JI D H. 心脉隆治疗冠心病心力衰竭的临床效果及对患者血浆hs-CRP、NT-proBNP水平的影响 [J]. The Journal of Medical Theory and Practice, 2019, 32 (16): 2543 (in Chinese).

    [30] GONG G H, LIU M, YANG J T. 心脉隆治疗冠心病心力衰竭的有效性及对相关指标的影响 [J]. Shenzhen Journal of Integrated Traditional Chinese and Western Medicine, 2018, 28 (14): 38 (in Chinese).

    [31] YANG X Q, XUE G M, CHANG Y, et al. 心脉隆注射液对冠心病心力衰竭患者BNP、尿酸的影响 [J]. Chinese Journal of Integrative Medicine on Cardio-Cerebrovascular Disease, 2015, 13 (6): 829 (in Chinese).

    [32] CHEN K J, WU Y G, ZHU M J, et al. 慢性心力衰竭中西医结合诊疗专家共识 [J]. Cardio-cerebrovascular Disease Prevention and Treatment, 2016, 16 (5): 340 (in Chinese).

    [33] GAO Y, LV J, XIE Y M, et al. 血栓通 (冻干粉)注射液治疗冠心病不稳定性心绞痛随机对照试验的有效性及安全性系统评价/Meta分析 [J]. China Journal of Chinese Materia Medica, 2019, 44 (20): 4366 (in Chinese).

    [34] BAI D , YUE G X, WANG R H, et al. Clinical characteristics of five traditional Chinese medicine injections in treating heart failure based on Meta-analysis literature [J]. China Journal of Chinese Materia Medica, 2018, 43 (20): 4152 (in Chinese).

    [35] Writing Group of National Compilation on Chinese Herbal Medicine. National Compilation on Chinese Herbal Medicine. Vol. Ⅱ [M]. Beijing: People's Medical Publishing House, 1978 (in Chinese).

    [36] WANG H W, WANG L Q, MENG Z H. 心脉隆注射液治疗心血管疾病研究进展 [J]. Chinese Journal of Modern Applied Pharmacy, 2019, 36 (23): 2995 (in Chinese).

    [37] XIN Y, DAI Y Y, YANG H X, et al. 稳心颗粒治疗慢性心力衰竭合并心房颤动的疗效性及安全性系统评价 [J]. China Journal of Chinese Materia Medica, 2019, 44 (23): 5198 (in Chinese).

    [38] CHENG W K, ZHAO M J, WANG L, et al. Myocardial substrate metabolic remodeling in heart failure [J]. Chinese Journal of Experimental Traditional Medical Formulae, 2020, 26 (5): 210 (in Chinese).

    [39] BAN J F, KE R. 脑心通胶囊联合西药治疗慢性心力衰竭的Meta分析 [J]. China Journal of Chinese Materia Medica, 2020, 45 (17): 4254 (in Chinese).

    [40] SUN Y L, RUAN X F, LI Y P, et al. 辨证论治应用芪苈强心胶囊对缺血性心力衰竭疗效影响的Meta分析比较 [J]. China Journal of Chinese Materia Medica, 2019, 44 (22): 4975 (in Chinese).

    [41] PUPIM L B, HIMMEIFARB J, MEMONAGLE E, et al. Influence of initiation of maintenance hemodialysis on biomarkers of inflammation and oxidative stress [J]. Kidney Int, 2004, 65 (6): 2371.

    [42] LIU H X, ZHU M J, MAO J Y, et al. 规范应用心脉隆注射液治疗慢性心力衰竭的专家共识 [J]. Chinese Journal of Integrated Traditional and Western Medicine, 2016, 36 (3): 280 (in Chinese).

    [43] TIAN C D, LV J, XIE Y M, et al. 茵栀黄口服液治疗新生儿黄疸的系统评价与Meta分析 [J]. China Journal of Chinese Materia Medica, 2019, 44 (24): 5303 (in Chinese).

This Article

ISSN:1001-5302

CN: 11-2272/R

Vol 45, No. 19, Pages 4756-4765

October 2020

Downloads:2

Share
Article Outline

Knowledge

Abstract

  • 1 Materials and methods
  • 2 Results
  • 3 Discussion
  • References